P atients with a clinical manifestation of vascular disease are generally considered to be at equally high risk of recurrent major vascular events and mortality. 1, 2 To reduce this risk, guidelines recommend strict targets for low-density lipoprotein (LDL) cholesterol and blood pressure, as well as for lifestyle risk factors. 1, 2 Whereas previous reports have demonstrated considerable variation in the risk of future vascular events in the primary prevention setting, 3, 4 little is known about the distribution of risk in patients with known vascular disease. Vascular event rates have declined over the last few decades. 5 With the emergence of novel therapeutic options for the prevention of (recurrent) vascular events such as anti-inflammatory agents and proprotein convertase subtilisin/kexin type 9 inhibitors, 6, 7 the question arises of whether patients with vascular disease can all be considered at high vascular risk, particularly if they are treated according to current guidelines. Insight into risk distributions, residual risk, and the additional risk reduction achieved with guideline-recommended targets may provide essential information to guide clinicians to the best therapeutic approach.
In the present study, we estimated the variation in 10year risk of recurrent vascular events among patients with clinically manifest vascular disease (coronary artery disease [CAD], cerebrovascular disease [CVD], peripheral artery disease [PAD] , or an abdominal aortic aneurysm [AAA]) using the SMART risk score (Second Manifestations of Arterial Disease). 8 The SMART risk score was recently developed, and external validity is essential before widespread use is justified. Therefore, we tested the performance of the SMART risk score in 3 external populations of patients with vascular disease originating from the TNT (Treating to New Targets), IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering), SPARCL (Stroke Prevention by Aggressive Reduction in Cholesterol Levels), and CAPRIE (Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events) trials. [9] [10] [11] [12] Furthermore, we estimated the risk reduction that might be achieved by reaching guideline-recommended risk factor targets and provide estimates of the residual risk in the secondary prevention setting.
MethODs study Population
Study participants originated from the SMART study, an ongoing prospective cohort study at the University Medical Center Utrecht in the Netherlands. A detailed description was published previously. 13 For the present study, we used data from 6904 patients enrolled between 1996 and 2013. At enrollment, patients were 18 to 80 years of age and were in a stable phase after a clinical manifestation of vascular disease, including CAD (n=3282), CVD (n=1491), PAD (n=805), an AAA (n=255), or polyvascular disease (vascular disease in ≥2 locations; n=1071). 8, 13 We excluded patients with a terminal malignancy and those who were not independent in activities of daily living or not sufficiently fluent in the Dutch language for purposes of informed consent. Risk factors were measured at enrollment with questionnaires, blood samples, and physical examination. More details on definitions of vascular disease, outcomes, and inclusion and exclusion criteria are presented in Tables I through III in the online-only Data Supplement. The SMART study complies with the Declaration of Helsinki; the University Medical Center Utrecht Ethics Committee approved the study; and all participants gave written informed consent.
risk of recurrent Vascular events
The estimated 10-year risk of the composite outcome of myocardial infarction, stroke, or cardiovascular death was calculated with the SMART risk score (Methods in the online-only Data Supplement) based on the following predictors: age; sex; current smoking; diabetes mellitus; systolic blood pressure (mm Hg); total cholesterol (mmol/L); high-density lipoprotein cholesterol (mmol/L); presence of CAD, CVD, PAD, or AAA; estimated glomerular filtration rate (mL·min −1 ·1.73 m −2 ); highsensitivity C-reactive protein (hsCRP; mg/L); and years since clinical Perspective What is new?
• Among patients with clinically manifest vascular disease, there is substantial variation in estimated 10-year risk of a recurrent major vascular event (myocardial infarction, stroke, or vascular death), with 18% of the patients at <10% 10-year risk and 22% at >30% 10-year risk. • If all vascular risk factors were at recommended targets according to secondary prevention guidelines, the 10-year residual risk would be estimated to be <10% for half of the patients with vascular disease. • However, even with optimal treatment, many patients with vascular disease will remain at >20% and even >30% 10-year risk.
What are the clinical implications?
• The general assumption that all patients with vascular disease are at high risk of recurrent vascular events needs to be refined. • In particular, with the emergence of novel options for further risk reduction such as anti-inflammatory agents and proprotein convertase subtilisin/ kexin type 9 inhibitors, a single secondary prevention strategy for all patients with vascular disease may no longer be appropriate. • Novel risk stratification approaches may be used to individualize secondary prevention by identifying high-risk patients to target those most likely to derive the greatest benefit from novel interventions.
ORIGINAL RESEARCH ARTICLE 1421 the first manifestation of vascular disease. 8 The estimated risks were plotted in histograms to show the variation in risk graphically. Because the risk of recurrent events is known to vary between patients with vascular disease in different locations, analyses were also performed with stratification for the location of vascular disease.
external Validity of the sMart risk score
We tested the external validity of the SMART risk score in 3 populations: in 9447 patients with CAD from the usual-dose statin arm of the TNT and IDEAL trials (http://www.ClinicalTrials.gov, unique identifiers NCT00327691 and NCT00159835), 11, 12 in 2366 patients with CVD from the placebo arm of the SPARCL trial (http://www.ClinicalTrials.gov, unique identifier NCT00147602), 9 and in 6623 patients with PAD from both arms of the CAPRIE trial. 10 It is notable that no suitable cohorts of patients with AAA or polyvascular disease were available for the present analyses (Methods in the online-only Data Supplement). Although patients with AAA (n=429) or polyvascular disease (n=4388) were represented in the 3 validation populations, further validation studies in these patient populations are required. Performance was assessed in terms of calibration (the agreement between predicted and observed risks) and discrimination (the extent to which patients who developed an event also had higher estimated risk than patients that did not experience the event of interest One therapeutic meta-analysis and 1 observational study that evaluated this relation showed no clear association. 14, 15 residual risk if Patients are at guidelinerecommended risk Factor targets
Estimates of the reducible and residual risks obtained by achieving guideline-recommended risk factor targets were derived from previous studies, as presented in Table V in the online-only Data Supplement. For the blood pressure, lipid, and antithrombotic/anticoagulant targets, effects from metaanalyses of randomized trials were used. [16] [17] [18] [19] For smoking cessation, a relative risk reduction of 0.74 was derived from a study in patients with CAD. 20 This is a relatively conservative estimate compared with a meta-analysis that showed hazard ratios of 0.68 for myocardial infarction and 0.64 for mortality separately. 21 This hazard ratio was chosen to prevent overoptimistic estimations of the reducible risk in these patients. For physical activity improvement, we used the effect on major vascular events in patients with diabetes mellitus with and without a history of vascular disease. 22 For the weight target, no effect on major vascular events was assumed because in secondary prevention settings the effect of intentional weight loss is not proven. 23 Moreover, the beneficial effects of weight reduction are also captured in the targets for physical activity, lipids, and systolic blood pressure. In addition, we considered potential associations between risk factors, that is, whether modifying 1 risk factor also influenced the levels of other risk factors (Table  VI in the online-only Data Supplement). On the basis of the available literature, we concluded that an increase in physical activity is likely to influence a patient's blood pressure. 24 Therefore, we performed a sensitivity analysis excluding the physical activity target from the analyses. It is important to note that we assumed that there were no interactions between the effects of risk factor modification on the reduction of vascular risk because data on potential interactions are limited and, across those subgroups examined, the relative risk reductions applied in the present study showed no clear heterogeneity. [16] [17] [18] statistical analysis
Analyses were performed with R statistical software version 3.1.1. 13 Missing data were imputed with 10-fold multiple imputation by predictive mean matching (R-package MICE), including other predictors and the outcome, assuming that these values were missing at random, and were pooled with the use of Rubin rules. 25, 26 In this method, the imputed value is taken from the observed values in the data set that are nearest to the predicted value of the missing variable based on covariate and outcome data. Missing data in SMART were ≤1% for smoking status, systolic blood pressure, total cholesterol, high-density lipoprotein cholesterol, estimated glomerular filtration rate, METs, history of CAD, CVD, or PAD, and years since first diagnosis of vascular disease; 2% for hsCRP; and 4% for LDL cholesterol. Missing data were <1% of each variable in the CAD external validation population; <1% for systolic blood pressure, total cholesterol, high-density lipoprotein cholesterol, and estimated glomerular filtration rate and 47% for CRP in the CVD external validation population; and <1% for years since first manifestation of vascular disease and estimated glomerular filtration rate, 7% for total cholesterol, 64% for systolic blood pressure and 71% for high-density lipoprotein cholesterol in the PAD external validation population. In the PAD validation population, the variable years since first manifestation of vascular disease applied to years since first manifestation of PAD even if patients also had CAD or CVD. For the unavailable variable hsCRP in the CAD and PAD validation cohorts, we imputed age-, sex-, and vascular disease-specific median values of hsCRP based on data from the SMART study (details are provided in Methods in the online-only Data Supplement). External validity of the SMART risk score was evaluated in terms of discrimination and calibration as described in detail in Methods in the online-only Data Supplement. Reducible and residual risks were calculated from the estimated 10-year risks and expected relative risk reductions for each target on the basis of previous literature ( Table V in the online-only Data Supplement). A detailed patient example of the calculations is provided in Table VII in the online-only Data Supplement. For the lipid goal, we first estimated the off-treatment LDL cholesterol level for patients who were already on lipid-lowering therapy on the basis of the average percentage LDL cholesterol reduction that is associated with the therapy that a patient already received. 27 Guideline-recommended control was defined as reaching a 50% reduction LDL cholesterol 1 or reaching the target of 2.6 mmol/L (high-risk patients) or 1.8 mmol/L (very-high-risk patients) 1,2 if this was a <50% reduction. On the basis of the estimated individual reduction of LDL cholesterol, a patient-specific relative risk reduction was used to estimate 10-year reducible and residual risks ( Table VII in the online-only Data Supplement). 17 For the blood pressure target, a similar approach was applied: Guideline-recommended control was defined as a maximum of 3 different classes of blood pressure-lowering agents for which an average reduction in systolic blood pressure was assumed 27 or reaching the target of <140 mm Hg if this was achieved with <3 agents. On the basis of the estimated systolic blood pressure reduction, the average effect of blood pressure-lowering agents on major vascular events per 5-mm Hg reduction in systolic blood pressure (hazard ratio of 0.83) was used to estimate the reducible risk.
Because guideline recommendations for treatment targets have changed over time, we performed a sensitivity analysis in the subset of patients enrolled in the period of 2008 to 2013, which is after the publication of the second most recent European Society of Cardiology and American Heart Association/American College of Cardiology Foundation guidelines for secondary prevention. 28, 29 results
Patient characteristics
Patient characteristics are shown stratified for their estimated risk in Table 1 and for location of vascular disease in Table 2 . On average, patients in the SMART cohort were 60 years old (SD, 10 years); 74% were male; 32% were current smokers; and 18% had a history of diabetes mellitus. Sixty percent of the patients had a history of CAD, 29% had CVD, 19% had PAD, and 9% had an AAA. Of these patients, 16% had vascular disease in ≥2 locations.
Variation in estimated 10-Year risk of recurrent Vascular events in Patients With Vascular Disease
There was wide variation in estimated 10-year risk of recurrent vascular events and mortality in patients with vascular disease, varying from <5% to >50% (median estimated risk, 17%; interquartile range [IQR], 11%-28%; Figure 1 ). Of the patients, 18% had a 10-year risk <10%, whereas 22% were at >30% 10-year risk. The estimated risk of recurrent vascular events varied substantially between patients with different clinical manifestations of vascular disease (Table 2) , with patients with CAD having the lowest risks (median 14%; IQR, 10%-20%) and patients with polyvascular disease having the highest risks (median, 35%; IQR, 23%-54%).
external Validation of the sMart risk score in tnt, iDeal, sParcl, and caPrie After recalibration in the CVD and PAD validation populations (SPARCL and CAPRIE) separately, calibration appeared reasonable in all 3 external populations ( Table  VIII in The overall median reducible risk was 5% (IQR, 2%-11%). This additional reducible risk was highest in patients with AAA (16%; IQR, 9%-22%) and lowest in patients with CAD (3%; IQR, 1%-6%). Figure 2 is an illustration of the reducible risk per risk factor stratified by location of vascular disease. After optimal control of risk factors as advocated in guidelines, the estimated residual 10-year risk of recurrent vascular events varied substantially (Figure 3) , with about half of the patients (47%) at <10% risk and 9% at >30% risk despite guideline-recommended control of risk factors. This residual risk also varied between patients with different types of vascular disease, with patients with polyvascular disease having the highest estimated residual risk (median, 22%; IQR, 14%-36%) and patients with PAD having the lowest estimated residual risk (median, 8%; IQR, 5%-12%), although marked variation in risk was still observed (Figure 3) .
Sensitivity analyses leaving out the physical activity target showed similar results for the estimates of reducible and residual risks. Sensitivity analyses of patients enrolled in the period of 2008 to 2013 showed similar results for the distribution in estimated 10-year risk and the estimated residual risk. On average, risk factor control was better in patients more recently enrolled between 2008 and 2013 compared with the total population, and as a consequence, the amount of reducible risk was lower in these patients, with a median of 3% (IQR, 1%-7%) compared with 5% (IQR, 2%-11%) in the total study population. This lower reducible risk in more recently treated patients was seen across all subgroups of patients with vascular disease and was still highest in patients with AAA (median, 8%; IQR, 4%-16%) and lowest in patients with CAD (2%; IQR, 1%-5%). Repeating the analyses using only patients with complete data (n=6219 [90% of the SMART population]) showed very similar results.
DiscussiOn
We found that patients with prevalent vascular disease display a substantial variation in estimated 10-year risk of recurrent vascular events. In fact, 18% of the patients are at relatively low 10-year risk (<10%), whereas 22% had an estimated risk of >30%. If all guideline-recommended targets were reached, the 10-year risk of recurrent vascular events could be reduced to <10% for (21) CVD, n (%) 282 (23) 667 (23) 283 (22) 260 (17) PAD, n (%) 88 (7) 393 (14) 175 (14) 149 (10) AAA, n (%) 3 (0) 32 (1) 64 (5) 156 (10) Polyvascular disease, n (%) 12 (1) 189 (7) 220 (17) 650 (42) Years since first vascular event 0 (0-1) 0 (0-1) 0 (0-6) 4 (0-15) about half of the patients with vascular disease. However, very large variation in the residual 10-year risk would still remain, with 20% of patients at >20% risk and 9% at even >30% risk of a recurrent vascular event.
Vascular event rates have declined over the last decades. 5 The present study demonstrates that simply considering all patients with vascular disease to be at (very) high risk for further vascular events does not reflect actual risk in these patients. Very few studies have reported the distribution of risk in patients with a history of vascular disease, 30 although from the primary prevention setting, we know that vascular prognosis varies greatly between patients. 3, 4 The observed variation in risk is a consequence of differences in the prevalence and levels of both modifiable and nonmodifiable risk factors (Table 1) . 31 This 10-year risk could be reduced with a median reducible risk of 5% if guideline-recommended targets were attained. The notion that "we can do better" is supported by our observation that better risk factor control between 2008 and 2013 resulted in fewer pos-sibilities for improvement, with a 10-year reducible risk of 3% in patients enrolled in this period. If all risk factors were at target, the risk of recurrent vascular events could be relatively low (10-year risk <10%) for about half of the patients with vascular disease. However there would still be substantial variation, with many patients at >20% and even >30% residual 10-year risk (Figure 3 ). Residual risk in patients with vascular disease is explained by modifiable risk factors such as on-treatment cholesterol levels, 32, 33 potentially modifiable risk factors such as inflammation, 6, 33 and nonmodifiable factors, including age and genetic predisposition.
Our findings may have several implications for clinical practice and future cardiovascular research. The large heterogeneity in estimated 10-year risk demonstrates that a single secondary prevention strategy for all patients with vascular disease may no longer be appropriate. Risk stratification may help to identify patients for intensive follow-up and to emphasize the importance of therapy adherence for reaching risk factor targets. Al- though adherence is known to be a persistent problem, 34 previous studies have shown that repeated communication of risk to patients results in significant improvements of modifiable risk factors. 35 Because the highest reducible risk was seen in patients with AAA, PAD, or polyvascular disease, such efforts to optimize risk factor treatment may yield most benefit in these patients. In addition, future research is necessary to reveal why targets are difficult to attain and how clinicians and patients can be best assisted to follow guideline recommendations. Nevertheless, even with the currently available options for risk reduction as advocated in secondary prevention guidelines, a clear unmet need in patients with vascular disease remains, with many patients at >20% and even >30% 10-year risk for recurrent events. 36 Several novel therapeutic options for cardiovascular prevention have the potential to address this unmet medical need and are currently under investigation in large outcome trials. For example, further lowering targets for traditional risk factors such as LDL cholesterol or using novel therapeutic targets such as inflammation may be considered. It is clear that more research is needed to assess the actual benefit of novel therapies for individual patients with vascular disease. 37, 38 The observed variation in risk supports risk stratification as a tool to select patients for cardiovascular trials. Because high-risk patients may yield the largest benefit in terms of lower numbers needed to treat with novel treatments, a risk-based selection of patients for cardiovascular trials may improve trial focus and efficiency. 36 The SMART risk score is a tool that may be used for these purposes. Its external validation in 3 separate populations shows reasonable performance. Although systematic overestimation of risk was seen among those with 10-year risk >40%, calibration was fairly good within the range of 0% to 40% estimated 10-year risk, which is more relevant for daily clinical practice and represents the majority of patients seen. The limited discriminatory ability is partly inherent to the population of interest. Selecting patients with a certain disease (in this case, vascular disease) results in a relatively homogeneous population in which it is more difficult to discriminate risk, especially in the specific subgroups of CAD, CVD, and PAD. In addition, we evaluated the performance in trial populations that are, because of strict inclusion and exclusion criteria, generally more homogeneous compared with observational studies ( Table I in the online-only Data Supplement). Therefore, discrimination is likely to be better in a more heterogeneous population, which is likely to be the case in clinical practice. Further optimization of the SMART risk score might improve risk estimation in these patients, for example, by adding less traditional but well-known predictors such as atrial fibrillation. 30 However, for the present population, the risk predictions are known to be accurate because the SMART risk score was developed in these patients.
Strengths of this study include the dynamic cohort design, representing clinical practice by including patients with different manifestations of vascular disease with long follow-up. A limitation is that, for the estimation of residual risk, the relative effects for the lifestyle targets smoking and physical activity were obtained from observational studies 20, 39 and thus are vulnerable to bias, especially confounding bias. Because the applied effects were adjusted for confounders and because limited heterogeneity in the relative effects was observed across several subgroups, we consider these estimates valid for our study population. Another limitation is that we performed external validation in trial populations with putative inclusion and exclusion criteria, relatively short follow-up, and limited availability of some of the predictors of the SMART risk score. Finally, the study population is from 1 academic center in the Netherlands, which may limit the generalizability of our findings. Because the participants originated from daily clinical practice with limited inclusion or exclusion criteria, we consider our findings generalizable to other populations with vascular disease. As a result of geographic variation in underlying event rates and risk factor prevalence, the median risks may vary between countries. 40 However, this does not affect the generalizability of our findings that there is substantial variation in both estimated and residual 10-year risk in patients with clinically manifest vascular disease.
cOnclusiOns
There is substantial variation in the estimated 10-year risk of recurrent vascular events in patients with vascular disease. About 18% of the patients were at relatively low risk (<10%) and 22% were at >30% risk. Improvements in reaching risk factors targets could reduce the 10-year risk to <10% in half of the patients with vascular disease; however, the residual risk still shows marked variation up to >30% 10-year risk. These findings demonstrate that considering all patients with vascular disease to be at equally high risk of a new vascular event is no longer valid. Instead, risk stratification can be used to further optimize cardiovascular disease prevention for patients with vascular disease. 
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